Selectivity determinants of the aldose and aldehyde reductase inhibitor-binding sites

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Cellular and Molecular Life Sciences

• Publication date

  2007-05-11

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s00018-007-6514-3PMID 17497245PMCID PMC11136326
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Factorizing selectivity determinants of inhibitor binding toward aldose and aldehyde reductases: structural and thermodynamic properties of the aldose reductase mutant Leu300Pro-fidarestat complex.

  2005cited by this paper
• Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.

  2005cited by this paper
• Selective Loss of AKR1C1 and AKR1C2 in Breast Cancer and Their Potential Effect on Progesterone Signaling

  2004cited by this paper
• Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with fidarestat and minalrestat: Implications for the binding of cyclic imide inhibitors

  2004cited by this paper
• Tibolone Is Metabolized by the 3α/3β-Hydroxysteroid Dehydrogenase Activities of the Four Human Isozymes of the Aldo-Keto Reductase 1C Subfamily: Inversion of Stereospecificity with a Δ5(10)-3-Ketosteroid

  2004cited by this paper
• Tibolone is metabolized by the 3alpha/3beta-hydroxysteroid dehydrogenase activities of the four human isozymes of the aldo-keto reductase 1C subfamily: inversion of stereospecificity with a delta5(10)-3-ketosteroid.

  2004cited by this paper
• Aldose Reductase-catalyzed Reduction of Aldehyde Phospholipids*

  2004cited by this paper
• Probing the ultra-high resolution structure of aldose reductase with molecular modelling and noncovalent mass spectrometry.

  2004cited by this paper
• High-resolution structures of human aldose reductase holoenzyme in complex with stereoisomers of the potent inhibitor Fidarestat: stereospecific interaction between the enzyme and a cyclic imide type inhibitor.

  2004cited by this paper
• Cloning and expression of two novel aldo-keto reductases from Digitalis purpurea leaves.

  2002cited by this paper
• Recent advances in aldose reductase inhibitors: potential agents for the treatment of diabetic complications

  2002cited by this paper
• The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome.

  2001cited by this paper
• [1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors.

  2001cited by this paper
• Stereospecific interaction of a novel spirosuccinimide type aldose reductase inhibitor, AS-3201, with aldose reductase.

  2001cited by this paper
• Aldose and aldehyde reductases: Correlation of molecular modeling and mass spectrometric studies on the binding of inhibitors to the active site

  2000cited by this paper
• Pharmacological approaches to the treatment of diabetic complications

  2000cited by this paper
• Aldose reductase and the role of the polyol pathway in diabetic nephropathy.

  2000cited by this paper
• A potent aldose reductase inhibitor, (2S,4S)-6-fluoro-2', 5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide (Fidarestat): its absolute configuration and interactions with the aldose reductase by X-ray crystallography.

  2000cited by this paper
• Kinetic and Structural Characterization of the Glutathione-binding Site of Aldose Reductase*

  2000cited by this paper
• Aldose and aldehyde reductases: structure-function studies on the coenzyme and inhibitor-binding sites.

  1999cited by this paper
• Members of the nuclear factor 1 transcription factor family regulate rat 3alpha-hydroxysteroid/dihydrodiol dehydrogenase (3alpha-HSD/DD AKR1C9) gene expression: a member of the aldo-keto reductase superfamily.

  1999cited by this paper
• Aldose reductase inhibitors: therapeutic implications for diabetic complications.

  1999cited by this paper
• Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites.

  1998cited by this paper
• Novel, highly potent aldose reductase inhibitors: (R)-(-)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4- tetrahydropyrrolo[1,2-a]pyrazine -4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (AS-3201) and its congeners.

  1998cited by this paper
• Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications.

  1998cited by this paper
• Identification of a principal mRNA species for human 3alpha-hydroxysteroid dehydrogenase isoform (AKR1C3) that exhibits high prostaglandin D2 11-ketoreductase activity.

  1998cited by this paper
• BENZOTHIAZOLE ALDOSE REDUCTASE INHIBITORS

  1998cited by this paper
• Aldose Reductase Inhibitors: The End of an Era or the Need for Different Trial Designs?

  1997cited by this paper
• A new nomenclature for the aldo-keto reductase superfamily.

  1997cited by this paper
• Comparative anatomy of the aldo-keto reductase superfamily.

  1997cited by this paper
• Studies on the inhibitor‐binding site of porcine aldehyde reductase: Crystal structure of the holoenzyme‐inhibitor ternary complex

  1997cited by this paper
• A 'specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil.

  1997cited by this paper
• The C-terminal loop of aldehyde reductase determines the substrate and inhibitor specificity.

  1996cited by this paper
• Increased levels of methylglyoxal-metabolizing enzymes in mononuclear and polymorphonuclear cells from insulin-dependent diabetic patients with diabetic complications: aldose reductase, glyoxalase I, and glyoxalase II--a clinical research center study.

  1996cited by this paper
• Mechanism of human aldehyde reductase: characterization of the active site pocket.

  1995cited by this paper
• Catalysis of reduction of carbohydrate 2-oxoaldehydes (osones) by mammalian aldose reductase and aldehyde reductase.

  1995cited by this paper
• Synthesis and aldose reductase inhibitory activity of 2-substituted 6-fluoro-2,3-dihydrospiro[4H-1-benzopyran-4,4'-imidazolidine]-2',5'-dio nes.

  1995cited by this paper
• Human aldose reductase: pK of tyrosine 48 reveals the preferred ionization state for catalysis and inhibition.

  1995cited by this paper
• Synthesis and aldose reductase inhibitory activity of 2-substituted-6-fluoro-2,3-dihydrospiro [4H-1-benzopyran-4, 4'-imidazolidine]-2',5'-diones.

  1994cited by this paper
• Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1.

  1994cited by this paper
• Mechanism of aldose reductase inhibition: binding of NADP+/NADPH and alrestatin-like inhibitors.

  1994cited by this paper
• N-substituted spirosuccinimide, spiropyridazine, spiroazetidine, and acetic acid aldose reductase inhibitors derived from isoquinoline-1,3-diones. 2.

  1994cited by this paper
• A perspective of aldose reductase inhibitors

  1993cited by this paper
• Aldose reductase inhibitors: recent developments.

  1993cited by this paper
• Molecular cloning of testicular 20 alpha-hydroxysteroid dehydrogenase: identity with aldose reductase.

  1993cited by this paper
• Catalytic effectiveness of human aldose reductase. Critical role of C-terminal domain.

  1992cited by this paper
• Novel NADPH-binding domain revealed by the crystal structure of aldose reductase

  1992cited by this paper
• Inhibition of aldehyde reductase by aldose reductase inhibitors.

  1990cited by this paper
• Enzymatic conversion of prostaglandin H2 to prostaglandin F2 alpha by aldehyde reductase from human liver: comparison to the prostaglandin F synthetase from bovine lung.

  1989cited by this paper
• Medicinal chemistry of aldose reductase inhibitors

  1988cited by this paper
• The involvement of aldose reductase in diabetic complications.

  1988cited by this paper
• Isolation and characterization of multiforms of aldehyde reductase in chicken kidney.

  1983cited by this paper
• Kinetic mechanisms in the reduction of aldehydes and ketones catalyzed by rabbit liver aldehyde reductases and hydroxysteroid dehydrogenases.

  1982cited by this paper
• Reductases for aromatic aldehydes and ketones from rabbit liver. Purification and characterization.

  1980cited by this paper
• Purification and properties of NADPH-dependent aldehyde reductase from human liver.

  1977cited by this paper
• Resolution and partial characterization of two aldehyde reductases of mammalian liver.

  1977cited by this paper
• Properties of the nicotinamide adenine dinucleotide phosphate-dependent aldehyde reductase from pig kidney. Amino acid composition, reactivity of cysteinyl residues, and stereochemistry of D-glyceraldehyde reduction.

  1975cited by this paper
• Purification and characterization of a reduced nicotinamide adenine dinucleotide phosphate-linked aldehyde reductase from brain.

  1970cited by this paper

• Old Target with New Vision: In Search of New Therapeutics for Diabetic Retinopathy by Selective Modulation of Aldose Reductase

  2026cites this paper
• Prognostic Potential of AKR1B1 in triple-negative breast cancer

  2025cites this paper
• Selectivity Challenges for Aldose Reductase Inhibitors: A Review on Comparative SAR and Interaction Studies

  2024cites this paper
• Risk factors for eye lens opacity in nuclear medicine workers – An overview

  2023cites this paper
• Characterization of the inhibition of aldose reductase with p-coumaric acid ethyl ester.

  2022cites this paper
• Overview of human 20 alpha-hydroxysteroid dehydrogenase (AKR1C1): Functions, regulation, and structural insights of inhibitors.

  2021cites this paper
• Perspective on the Structural Basis for Human Aldo-Keto Reductase 1B10 Inhibition

  2021influential citation
• Exploring synthetic and therapeutic prospects of new thiazoline derivatives as aldose reductase (ALR2) inhibitors

  2021cites this paper
• Synthesis of indole substituted thiosemicarbazones as an aldose reductase inhibitor: an in vitro, selectivity and in silico study.

  2021cites this paper
• Addressing selectivity issues of aldose reductase 2 inhibitors for the management of diabetic complications.

  2020cites this paper
• 3D-QSARs and molecular dynamics simulation studies on induced fit binding of flavones to human aldose reductase

  2020cites this paper
• Systematic review on anti-diabetic properties of chalcones.

  2020cites this paper
• Comparative proteomic analysis of three Lactobacillus plantarum under salt stress by iTRAQ.

  2020cites this paper
• Regulation of Gluconeogenesis by Aldo-keto-reductase 1a1b in Zebrafish

  2020cites this paper
• Dihydrobenzoxazinone derivatives as aldose reductase inhibitors with antioxidant activity.

  2020cites this paper
• (5-Hydroxy-4-oxo-2-styryl-4H-pyridin-1-yl)-acetic Acid Derivatives as Multifunctional Aldose Reductase Inhibitors

  2020cites this paper
• Aldose reductase inhibitors: 2013-present

  2019cites this paper
• Molecular modelling and synthesis of spiroimidazolidine-2,4-diones with dual activities as hypoglycemic agents and selective inhibitors of aldose reductase.

  2018cites this paper
• Enzymes inhibitors from natural sources with antidiabetic activity: A review

  2018cites this paper
• Design, synthesis, structure-activity relationships and X-ray structural studies of novel 1-oxopyrimido[4,5-c]quinoline-2-acetic acid derivatives as selective and potent inhibitors of human aldose reductase.

  2018cites this paper
• Dihydroxanthyletin-type coumarins from Angelica decursiva that inhibits the formation of advanced glycation end products and human recombinant aldose reductase

  2017cites this paper
• Identification of new potent inhibitor of aldose reductase from Ocimum basilicum.

  2017cites this paper
• Exploration of thioxothiazolidinone-sulfonate conjugates as a new class of aldehyde/aldose reductase inhibitors: A synthetic and computational investigation.

  2017cites this paper
• Nutraceuticals in prevention of cataract – An evidence based approach

  2016cites this paper
• Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment

  2016cites this paper
• Functional and structural studies of AKR1B15 and AKR1B16: Two novel additions to human and mouse aldo-keto reductase superfamily

  2016cites this paper
• Amelioration of Bleomycin-induced Pulmonary Fibrosis of Rats by an Aldose Reductase Inhibitor, Epalrestat

  2015cites this paper
• Kinetic and molecular docking studies of loganin and 7-O-galloyl-d-sedoheptulose from Corni Fructus as therapeutic agents for diabetic complications through inhibition of aldose reductase

  2015cites this paper
• Targeting aldose reductase for the treatment of diabetes complications and inflammatory diseases: new insights and future directions.

  2015cites this paper
• Structural Determinants of the Selectivity of 3‐Benzyluracil‐1‐acetic Acids toward Human Enzymes Aldose Reductase and AKR1B10

  2015cites this paper
• Effect of Myrcia guianensis (Pedra-ume-caa) infusion on Wistar rat glycemia and lipidemia

  2015cites this paper
• Identification of a novel polyfluorinated compound as a lead to inhibit the human enzymes aldose reductase and AKR1B10: structure determination of both ternary complexes and implications for drug design.

  2014influential citation
• Kinetic and molecular docking studies of loganin and 7-O-galloyl-d-sedoheptulose from Corni Fructus as therapeutic agents for diabetic complications through inhibition of aldose reductase

  2014cites this paper
• Evaluation of in vitro aldose reductase inhibitory potential of alkaloidal fractions of Piper nigrum, Murraya koenigii, Argemone mexicana, and Nelumbo nucifera

  2014cites this paper
• Structural Basis for the Inhibition of AKR1B10 by Caffeic Acid Phenethyl Ester (CAPE)

  2014cites this paper
• Benzothiazolyl substituted iminothiazolidinones and benzamido-oxothiazolidines as potent and partly selective aldose reductase inhibitors

  2014cites this paper
• Alkaloids as Aldose Reductase Inhibitors, with Special Reference to Berberine

  2014influential citation
• Challenges in docking 2′-hydroxy and 2′,4′-dihydroxychalcones into the binding site of ALR2

  2013cites this paper
• Kinetics and molecular docking studies of an anti-diabetic complication inhibitor fucosterol from edible brown algae Eisenia bicyclis and Ecklonia stolonifera.

  2013cites this paper
• Aldose Reductase Inhibition Prevents Colon Cancer Growth by Restoring Phosphatase and Tensin Homolog Through Modulation of miR-21 and FOXO3a

  2013cites this paper
• X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.

  2013cites this paper
• Crystal packing modifies ligand binding affinity: The case of aldose reductase

  2012cites this paper
• Kinetics and molecular docking studies of kaempferol and its prenylated derivatives as aldose reductase inhibitors.

  2012cites this paper
• A potential therapeutic role for aldose reductase inhibitors in the treatment of endotoxin-related inflammatory diseases

  2012cites this paper
• Partial Inhibition of Aldose Reductase by Nitazoxanide and Its Molecular Basis

  2012cites this paper
• Biological Role of Aldo–Keto Reductases in Retinoic Acid Biosynthesis and Signaling

  2012cites this paper
• - 1-Structure-based enzyme inhibition mechanism studies of kaempferol and its prenylated derivatives as aldose reductase inhibitors using kinetics and molecular docking modeling

  2011influential citation
• Eye Lens in Aging and Diabetes: Effect of Quercetin

  2011cites this paper
• Natural flavonoids as potential multifunctional agents in prevention of diabetic cataract

  2011cites this paper
• nhibitors of human 20-hydroxysteroid dehydrogenase ( AKR 1 C 1 )

  2011cites this paper
• Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10.

  2010cites this paper
• Efeito da infusão de Myrcia guianensis (Pedra-ume-caa) na glicemia e lipemia de ratos Wistar

  2010cites this paper
• Design and synthesis of novel series of pyrrole based chemotypes and their evaluation as selective aldose reductase inhibitors. A case of bioisosterism between a carboxylic acid moiety and that of a tetrazole.

  2010cites this paper
• A diverse series of substituted benzenesulfonamides as aldose reductase inhibitors with antioxidant activity: design, synthesis, and in vitro activity.

  2010cites this paper
• Aldo-keto reductase family 1 member B1 inhibitors: old drugs with new perspectives.

  2009cites this paper
• Structural and biochemical analyses of YvgN and YtbE from Bacillus subtilis

  2009cites this paper
• Discovery of [3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2,3-b]pyridin-1-yl]acetic acids as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.

  2009cites this paper
• Aldose reductase, still a compelling target for diabetic neuropathy.

  2008cites this paper
• Inhibitory activities of prenylated flavonoids from Sophora flavescens against aldose reductase and generation of advanced glycation endproducts

  2008cites this paper
• Structural and functional features of dimeric dihydrodiol dehydrogenase

  2008cites this paper
• Inhibitory activities of the alkaloids from Coptidis Rhizoma against aldose reductase

  2008cites this paper
• Selectivity determinants of inhibitor binding to human 20alpha-hydroxysteroid dehydrogenase: crystal structure of the enzyme in ternary complex with coenzyme and the potent inhibitor 3,5-dichlorosalicylic acid.

  2008cites this paper
• Barley aldose reductase: Structure, cofactor binding, and substrate recognition in the aldo/keto reductase 4C family

  2008cites this paper
• The Polyol Pathway and Diabetic Retinopathy

  2008cites this paper
• Carboxymethylated pyridoindole antioxidants as aldose reductase inhibitors: Synthesis, activity, partitioning, and molecular modeling.

  2008cites this paper
• Inhibition of 3(17)alpha-hydroxysteroid dehydrogenase (AKR1C21) by aldose reductase inhibitors.

  2008cites this paper